\
&
Contact us
\
&
Contact us
Published on | 2 months ago
Programmes Culture and society EITThe European institute of Innovation and Technology (EIT) tries to build the bridge from promising innovations to succesful businesses. It counts about 10 knowledge and innovation communities (KIC) that focus on a specific sector. The EIT Culture and Creativity is one of the more recently established newer KIC's.
To help businesses cross this bridge it has launched a call for applications for two tailored business support programmes designed to accelerate the growth of promising start-ups and scale-ups in Europe’s cultural and creative sectors and industries (CCSI). The focus is on five key sectors: fashion, architecture, cultural heritage, audio-visual media, and gaming.
You can apply if you are a start-up or scale-up operating in one or more CCSI sectors, legally established in an EU Member State or a Horizon Europe-associated country. Applicants must meet the SME criteria, have at least two years of operations, and a product or service on the market.
The application deadline for cohort 1 has passed but you can still apply for cohort 2 untill the 11th of July 2025. You can find all the application details here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
